<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157857</url>
  </required_header>
  <id_info>
    <org_study_id>OSNA in EBUS-TBNA</org_study_id>
    <nct_id>NCT02157857</nct_id>
  </id_info>
  <brief_title>One Step Nucleic Acid Amplification in Endobronchial Ultrasound-guided Needle Aspiration Samples</brief_title>
  <official_title>A Molecular Test for Rapid On-site Evaluation in EBUS-TBNAsamples of Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to investigate if CK19 mRNA-detection via OSNA can accurately detect
      lymph node metastases in lung cancer patients using EBUS-TBNA samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regional lymph nodes are assessed before tumor resection and before initiation of chemo- or
      radiotherapy. Endobronchial ultrasound-guided needle aspiration (EBUS-TBNA) is a
      well-established method for mediastinal and hilar lymph node staging [2, 3]. Samples obtained
      via this route are much smaller than surgical lymph node biopsies, yet they are able to
      provide complete and thorough evaluation, this includes current molecular testing.

      One Step Nucleic Acid Amplification (OSNA), a molecular test that utilizes CK 19
      mRNA-concentration as a target marker is becoming a rapidly dynamic method in quick detection
      of sentinel lymph node (SLN) metastases in breast cancer, colon cancer and other cancers.

      In lung cancer, the role of SLN is not well established. However, recent publications suggest
      an accurate and rapid detection of lymph node metastases in NSCLC. However this requires
      complete lymph node dissection either with mediastinoscopy or by other surgical means such as
      thoracotomy.

      The aim of our study is to investigate if CK19 mRNA-detection via OSNA can accurately detect
      lymph node metastases in lung cancer patients using EBUS-TBNA samples.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>One step nucleic acid amplification of Cytokeratin 19 mRNA</measure>
    <time_frame>6 months</time_frame>
    <description>One step nucleic acid amplification of Cytokeratin 19 mRNA, copy number detection</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Endobronchial ultrasound-guided needle-aspiration samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CT-scans suspicious for primary diagnosis of lung cancer and enlarged
        mediastinal lymph nodes Patients with known diagnosis of lung cancer and newly enlarged
        mediastinal lymph nodes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CT-scan suspicious for lung cancer,

          -  enlarged mediastinal lymph nodes (&gt;10 mm),

          -  EBUS-TBNA to be performed,

          -  age: 18-99 years

        Exclusion Criteria:

          -  age: &lt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaid Darwiche, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filiz Oezkan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filiz Oezkan, MD</last_name>
    <phone>00492014334634</phone>
    <email>filiz.oezkan@ruhrlandklinik.uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaid Darwiche, MD</last_name>
    <phone>00492014334552</phone>
    <email>kaid.darwiche@ruhrlandklinik.uk-essen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruhrlandklinik</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filiz Oezkan, MD</last_name>
      <phone>00492014334634</phone>
      <email>filiz.oezkan@ruhrlandklinik.uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Kaid Darwiche, MD</last_name>
      <phone>00492014334552</phone>
      <email>kaid.darwiche@ruhrlandklinik.uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Filiz Oezkan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Yasufuku K, Pierre A, Darling G, de Perrot M, Waddell T, Johnston M, da Cunha Santos G, Geddie W, Boerner S, Le LW, Keshavjee S. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg. 2011 Dec;142(6):1393-400.e1. doi: 10.1016/j.jtcvs.2011.08.037. Epub 2011 Oct 2.</citation>
    <PMID>21963329</PMID>
  </reference>
  <reference>
    <citation>Inoue M, Hiyama K, Nakabayashi K, Morii E, Minami M, Sawabata N, Shintani Y, Nakagiri T, Susaki Y, Maeda J, Higashiyama M, Okami J, Yoshida Y, Ding J, Otomo Y, Okumura M. An accurate and rapid detection of lymph node metastasis in non-small cell lung cancer patients based on one-step nucleic acid amplification assay. Lung Cancer. 2012 Dec;78(3):212-8. doi: 10.1016/j.lungcan.2012.08.018. Epub 2012 Sep 29.</citation>
    <PMID>23026640</PMID>
  </reference>
  <reference>
    <citation>Babar M, Madani R, Thwaites L, Jackson PA, Devalia HL, Chakravorty A, Irvine TE, Layer GT, Kissin MW. A differential intra-operative molecular biological test for the detection of sentinel lymph node metastases in breast carcinoma. An extended experience from the first U.K. centre routinely offering the service in clinical practice. Eur J Surg Oncol. 2014 Mar;40(3):282-8. doi: 10.1016/j.ejso.2013.10.030. Epub 2013 Nov 21.</citation>
    <PMID>24331309</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Filiz Oezkan</investigator_full_name>
    <investigator_title>Dr. med. Filiz Oezkan</investigator_title>
  </responsible_party>
  <keyword>NSCLC, SCLC, lung cancer, EBUS-TBNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 13, 2015</submitted>
    <returned>November 17, 2015</returned>
    <submitted>November 23, 2016</submitted>
    <returned>January 18, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

